This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
HomeSearch

Menu

Close

SerotypesSerotypesSerotype CoverageSerotype SelectionCase CoverageEfficacyEfficacyInvasive Pneumococcal DiseaseOtitis MediaClinical Trial Results

Clinical Trial
Results

Study DesignImmunogenicitySafety ProfileDosing & Recommendations

Dosing &
Recommendations

DosingAdherenceDisease BurdenDisease BurdenDisease BurdenDisparitiesAccess & SupportAccess &
SupportOrder Prevnar 20®Commercial health plansEventsMaterialsVideosGeneral Inquiries
Prescribing InformationPatient InformationIndications Patient Site
Prevnar 20® achieved a 1.5- to 6.5-fold increase in antibody levels after dose 4 in babies in the pivotal study1*Among children, the highest rate of IPD occurred in those under 2 years of age2 IPD can be a serious condition for babies3

Learn about the risks of IPD caused by Streptococcus pneumoniae

Understand the disease burden
LoadingDosing & Recommendations Download Digital Dosing Tool

For appropriate dosing of Prevnar 20 for eligible infants and children.

 Get the tool LoadingGMC=geometric mean concentration; IgG=immunoglobulin G; IPD=invasive pneumococcal disease.
*Pneumococcal antipolysaccharide IgG GMCs were calculated from blood samples taken from 831-833 infants and 753-755 toddlers who received a 4-dose series of Prevnar 20.1References:Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report: Emerging Infections Program Network. Streptococcus pneumoniae, 2022. Updated July 5, 2024. Accessed February 25, 2025. 
https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2022.pdfGierke R, Wodi AP, Kobayashi M. Pneumococcal disease. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds.
Epidemiology and Prevention of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention. 14th ed. Public Health Foundation; 2021:255-274.
Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-2905 © 2025 Pfizer Inc.
All rights reserved. June 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2905
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
INDICATIONS 
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups, and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and risks
  • In individuals 2, 4, 6, and 12 through 15 months of age vaccinated with a 4-dose schedule, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, decreased appetite, injection site redness, injection site swelling, and fever
  • In individuals 15 months through 17 years of age vaccinated with a single dose, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, fatigue and muscle pain, decreased appetite, injection site swelling and redness, headache, and fever
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.INDICATIONSIndications
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age